Effect of miglitol, an alpha-glucosidase inhibitor, on atherogenic outcomes in balloon-injured diabetic rats. 2009

A Hirata, and M Igarashi, and H Iwai, and M Tominaga
Department of Laboratory Medicine, Yamagata University School of Medicine, Yamagata, Japan.

This study investigates the effects of miglitol, an alpha-glucosidase inhibitor, on the development of balloon-injured neointimal thickening in left common carotid artery, and the changes of glucose metabolism and inflammatory responses in Wistar fatty rats, an obese-hyperglycemic animal model, and their littermates, Wistar lean rats. Miglitol was orally administered at 40 mg/100 g of high-fat diet containing 45% kcal as fat to 12-week-old rats for 29 days, and age-matched rats without the agent were used as the respective controls. Balloon catheterization in the left common carotid artery was performed on day 15, and the artery was removed on day 29. Compared with the area ratio of the neointima/media in fatty rats without treatment, those in fatty rats with miglitol and lean rats without treatment were significantly decreased to 80%. The administration of miglitol significantly decreased the levels of plasma glucose, glycoalbumin and high-sensitivity C-reactive protein, and elevated the high-density lipoprotein-cholesterol level in fatty rats. These findings suggest that miglitol could be effective for the suppression of atherogenic outcomes in diabetic Wistar fatty rat, suggesting that the agent may have clinical benefits and contribute to prevent diabetic macroangiopathy.

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D008297 Male Males
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D002404 Catheterization Use or insertion of a tubular device into a duct, blood vessel, hollow organ, or body cavity for injecting or withdrawing fluids for diagnostic or therapeutic purposes. It differs from INTUBATION in that the tube here is used to restore or maintain patency in obstructions. Cannulation,Cannulations,Catheterizations
D003921 Diabetes Mellitus, Experimental Diabetes mellitus induced experimentally by administration of various diabetogenic agents or by PANCREATECTOMY. Alloxan Diabetes,Streptozocin Diabetes,Streptozotocin Diabetes,Experimental Diabetes Mellitus,Diabete, Streptozocin,Diabetes, Alloxan,Diabetes, Streptozocin,Diabetes, Streptozotocin,Streptozocin Diabete
D004041 Dietary Fats Fats present in food, especially in animal products such as meat, meat products, butter, ghee. They are present in lower amounts in nuts, seeds, and avocados. Fats, Dietary,Dietary Fat,Fat, Dietary
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D017208 Rats, Wistar A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain. Wistar Rat,Rat, Wistar,Wistar Rats
D017485 1-Deoxynojirimycin An alpha-glucosidase inhibitor with antiviral action. Derivatives of deoxynojirimycin may have anti-HIV activity. 1,5-Deoxy-1,5-imino-D-mannitol,1-Deoxymannojirimycin,1,5-Dideoxy-1,5-imino-D-mannitol,1-Deoxynojirimycin Hydrochloride,Bay n 5595,Moranoline,1 Deoxymannojirimycin,1 Deoxynojirimycin,1 Deoxynojirimycin Hydrochloride
D050197 Atherosclerosis A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA. Atherogenesis,Atherogeneses,Atheroscleroses

Related Publications

A Hirata, and M Igarashi, and H Iwai, and M Tominaga
November 1999, Expert opinion on pharmacotherapy,
A Hirata, and M Igarashi, and H Iwai, and M Tominaga
May 2000, MMW Fortschritte der Medizin,
A Hirata, and M Igarashi, and H Iwai, and M Tominaga
August 1997, Diabetes research and clinical practice,
A Hirata, and M Igarashi, and H Iwai, and M Tominaga
December 2007, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan,
A Hirata, and M Igarashi, and H Iwai, and M Tominaga
January 1993, The Journal of international medical research,
A Hirata, and M Igarashi, and H Iwai, and M Tominaga
May 2013, Metabolism: clinical and experimental,
A Hirata, and M Igarashi, and H Iwai, and M Tominaga
September 1995, Current eye research,
A Hirata, and M Igarashi, and H Iwai, and M Tominaga
March 2006, Nihon yakurigaku zasshi. Folia pharmacologica Japonica,
A Hirata, and M Igarashi, and H Iwai, and M Tominaga
April 1992, Diabetes care,
Copied contents to your clipboard!